Develops therapies for neurological disorders, specifically targeting chronic pruritus and other central nervous system conditions.
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to advancing innovative treatments for serious neurologically mediated conditions. At the forefront of its development efforts is Haduvio, an oral extended-release formulation of nalbuphine. Haduvio is currently undergoing phase IIb/III clinical trials for the treatment of chronic pruritus and chronic cough in patients with idiopathic pulmonary fibrosis.
In pursuit of its therapeutic goals, Trevi Therapeutics has entered into a strategic license agreement with Endo Pharmaceuticals Inc. This collaboration enables the development and potential commercialization of products incorporating nalbuphine hydrochloride in various formulations, further expanding the company's reach and impact in the pharmaceutical industry.
Founded in 2011, Trevi Therapeutics is headquartered in New Haven, Connecticut, strategically positioning itself within a vibrant biopharmaceutical hub. Since its inception, the company has been driven by a mission to address significant unmet medical needs through innovative research and development efforts.
With a robust pipeline and a commitment to scientific excellence, Trevi Therapeutics is poised to make meaningful advancements in the treatment landscape of neurologically mediated conditions. Through its pioneering approach, the company aims to improve the lives of patients worldwide by delivering novel therapeutic solutions.